Business Wire

GN-HEARING

18.8.2020 09:02:06 CEST | Business Wire | Press release

Share
ReSound ONE: an entirely new class of hearing aids that offers a truly individualized hearing experience and the best sound quality for every user

GN Hearing, the global leader in hearing aid innovation, today unveils ReSound ONETM , a revolutionary new hearing aid* that solves one of the most enduring challenges for people with hearing loss. This unique solution places an additional microphone inside the ear canal, for the first time, allowing people relying on hearing aids to experience the world with their own ears while preserving the comfort of an open-fit device. Now every user can enjoy the benefits of superior sound quality and hear conversations better in noisy environments.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200818005077/en/

With its Organic Hearing philosophy, GN has always taken its design inspiration from how humans hear naturally and seeks to mimic this within its technology as closely as possible. Following this approach, ReSound ONE uniquely adapts to the needs and lifestyle of every individual rather than the other way around.

The outer ear (pinna) is designed by nature to work like an acoustic antenna. It helps the brain localize and tune in to a particular sound, for example when listening to a specific voice in a crowded café. However, the most popular styles of hearing aids (Receiver-In-Ear and Behind-The-Ear models) capture sound from microphones that sit behind the ear and then approximate the effect of the pinna. The result is an averaged and incomplete reproduction of sound, making it hard for the brain to achieve its natural localization and noise-cancelling function. In fact, of the 79 million people who wear hearing aids globally,1 93% report having trouble hearing in noisy environments and 55% get confused about where sounds come from.2

ReSound ONE is the world’s first full-featured* hearing aid with a Microphone & Receiver-In-Ear design (M&RIE) that uses the unique shape of every individual’s ear to collect sound. This remarkable innovation has been achieved with a radical new receiver system combined with all-new Digital Feedback Suppression (DFS Ultra III), enabled by GN’s new and most powerful sound-processing chipset ever. By picking up sound directly inside the ear, ReSound ONE gives the brain everything it needs to tune in to individual voices, as well as significantly reducing background noise. Clinical studies show that all hearing aid users benefit from listening to sounds collected with their own ears, with 90% of users preferring the sound quality of ReSound ONE with M&RIE instead of only the microphone behind the ear.3,4

GN Hearing CEO and President, Gitte Aabo explains, “I am very proud that, once again, GN is first in the industry with ground-breaking innovation that will make a genuine difference in how people experience conversations and sounds around them. Placing a microphone into the ear with an open-fit hearing aid is something the industry has battled for many years to achieve. This technology will allow people with hearing loss to feel that they are literally getting their own hearing back and hearing the way nature intended. ReSound ONE will boost the communication, relationships, and confidence of every individual.”

Additionally, ReSound ONE incorporates new All Access Directionality and the user-activated Ultra Focus settings. These enhanced operating modes significantly improve speech recognition while preserving spatial perception in complex sound and noise situations. ReSound ONE includes unmatched rechargeability and extensive connectivity options to both iOS and Android™ smartphones for streaming and hearing aid control.

ReSound ONE is available from August 27, 2020 in rechargeable and non-rechargeable models. This technology is also available in new Beltone Imagine hearing aids.

For further information, visit the ReSound Newsroom and read more about the Organic Hearing philosophy.

Learn more about GN’s 2020 and beyond strategy with focus on individualized customer experiences.

- ENDS –

NOTES TO EDITORS

About ReSound

ReSound hearing aids, available from leading hearing care professionals, continue to set worldwide standards for quality and intuitive technology to help people with hearing loss communicate better than ever before. ReSound was the first hearing aid brand to be Made for iPhone, bringing direct streaming from hearing aids into the iPhone era. It also pioneered the development of 2.4 GHz wireless technology and made it possible to receive advanced at-home hearing care during COVID-19. The introduction of this new class of hearing technology with ReSound ONE demonstrates that ReSound is the undisputed innovation leader putting people with hearing loss at the center. Featuring award winning technology, ReSound has been trusted for decades by people with hearing loss and their caregivers around the world.

About GN Group

The GN Group enables people to Hear More, Do More and Be More through its intelligent hearing, audio and video collaboration solutions. Inspired by people and driven by our innovation leadership, we leverage technological synergies between our hearing and audio divisions to deliver unique and increasingly individualized user experiences in our products and solutions.

150 years ago, GN was founded with a truly innovative and global mindset. Today, we honor that legacy with world-leading expertise in the human ear, sound and video processing, wireless technology, miniaturization and collaborations with leading technology partners. GN's solutions are marketed by the brands ReSound, Beltone, Interton, Jabra, BlueParrott and FalCom in 100 countries. Founded in 1869, the GN Group employs 6,500 people and is listed on Nasdaq Copenhagen (GN.CO).

​​Visit our homepage GN.com, get to know our innovation and leadership​ ​​, and connect with us on LinkedIn , Facebook and Twitter .

*ReSound ONE introduces the world’s first full-featured hearing aid with M&RIE for a truly individualized, more complete sound experience. Full-featured means a microphone in the ear and two additional, standard directional microphones, directionality features and wireless audio streaming.

© 2020 GN Hearing A/S. All rights reserved. ReSound is a trademark of GN Hearing A/S. Beltone is a trademark of GN Hearing Care Corporation. Apple, the Apple logo, iPhone, iPad and iPod touch are trademarks of Apple Inc., registered in the U.S. and other countries. Android is a trademark of Google LLC.

References

  1. World Health Organization (2020) Deafness and hearing loss. Factsheet. https://www.who.int/news-room/fact-sheets/detail/deafness-and-hearing-loss . Accessed: July, 2020
  2. MarkeTrak 2019
  3. Jespersen et al (2020): M&RIE receiver preferred for sound quality and localization. ReSound white paper
  4. Groth J. (2020). An innovative RIE with microphone in the ear lets users “hear with their own ears”. ReSound white paper

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme

Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release

Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting

Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release

On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-

Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release

Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac

The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 22:22:00 CEST | Press release

The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye